Antisense inhibition of β1-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats

Circulation

Volumn 101, Issue 6, 2000, Pages 682-688

  Zhang, Yuan Clare ^a   Bui, Jonathan D ^a   Shen, Leping ^a   Phillips, M Ian ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Contractility; Gene therapy; Hypertension; Receptors, adrenergic, beta

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ALPRENOLOL; ANTISENSE OLIGONUCLEOTIDE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYANOIODOPINDOLOL; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOBUTAMINE; ISOPRENALINE; LIPOSOME; MESSENGER RNA; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; AUTORADIOGRAPHY; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; GENE THERAPY; HEART MUSCLE CONTRACTILITY; HEMODYNAMICS; HYPERTENSION; INOTROPISM; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0034651711     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.6.682     Document Type: Article

References (26)

1. Sproat TT, Lopez LM. Around the beta-blockers, one more time. DICP. 1991;25:962-971.
2. Phillips MI, Ambuhl P, Gyurko R. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension. 1997;29:177-187.
3. Akhtar S, Rossi JJ. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? J Antimicrob Chemother. 1996;38:159-165.
4. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res. 1997;9:313-325.
5. Yla HS. Vascular gene transfer. Curr Opin Lipidol. 1997;8:72-76.
6. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA. 1991;88:7595-7599.
7. 1 angiotensin receptor mRNA in spontaneously hypertensive rats. Am J Hypertens. 1997;10:56S-62S.
8. Iversen P. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des. 1991;6:531-538.
9. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol. 1995;49:929-939.
10. Machida CA, Bunzow JR, Searles RP, Van TH, Tester B, Neve KA, Teal P, Nipper V, Civelli O. Molecular cloning and expression of the rat beta-1-adrenergic receptor. J Biol Chem. 1990;265:12960-12965.
11. Tang F, Hughes JA. Introduction of a disulfide bond into a cationic lipid enhances transgene expression of plasmid DNA. Biochem Biophys Res Commun. 1998;242:141-145.
12. Baker SP, Pitha J. Irreversible blockade of beta adrenoreceptors and their recovery in the rat heart and lung in vivo. J Pharmacol Exp Ther. 1982;220:247-251.
13. Matthews JM, Molenaar P, Summers RJ. Beta-adrenoceptor subtypes in the atrioventricular conducting system and myocardium of spontaneously hypertensive rats: effects of angiotensin-converting enzyme inhibition by perindopril. J Cardiovasc Pharmacol. 1994;23:691-697.
14. Neve KA, Molinoff PB. Turnover of beta 1-and beta 2-adrenergic receptors after down-regulation or irreversible blockade. Mol Pharmacol. 1986;30:104-111.
15. Winter RJ, Inkpen PM, Dickinson KE, Rudd RM, Sever PS. De novo cardiac beta adrenoceptor synthesis in adult rats under normoxic and hypoxic conditions. Cardiovasc Res. 1988;22:159-162.
16. Bazil MK, Krulan C, Webb RL. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993;22:897-905.
17. Allen TM. Liposomes: opportunities in drug delivery. Drugs. 1997; 54(suppl 4):8-14.
18. Liu Y, Mounkes LC, Liggitt HD, Brown CS, Solodin I, Heath TD, Debs RJ. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol. 1997;15:167-173.
19. Yang JP, Huang L. Time-dependent maturation of cationic liposome-DNA complex for serum resistance. Gene Ther. 1998;5: 380-387.
20. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998;70:1781-1792.
21. McLean JW, Fox EA, Baluk P, Bolton PB, Haskell A, Pearlman R, Thurston G, Umemoto EY, McDonald DM. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol. 1997;273:H387-H404.
22. Schackert G, Fan D, Nayar R, Fidler IJ. Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases. Sel Cancer Ther. 1989;5:73-79.
23. Chang EH, Yu Z, Shinozuka K, Zon G, Wilson WD, Strekowska A. Comparative inhibition of ras p21 protein synthesis with phosphorus-modified antisense oligonucleotides. Anticancer Drug Des. 1989;4: 221-232.
24. Brown L, Deighton NM, Bals S, Sohlmann W, Zerkowski HR, Michel MC, Brodde OE. Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol. 1992;19:222-232.
25. Kaumann AJ. The beta 1-adrenoceptor antagonist CGP 20712 A unmasks beta 2-adrenoceptors activated by (-)-adrenaline in rat sinoatrial node. Naunyn Schmiedebergs Arch Pharmacol. 1986;332:406-409.
26. Rodefeld MD, Beau SL, Schuessler RB, Boineau JP, Saffitz JE. Beta-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high beta 2-adrenergic receptor density. J Cardiovasc Electrophysiol. 1996;7:1039-1049.